Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Thymosin Beta 4 (TB-500) and Tissue Repair

Thymosin Beta 4 (TB-500) and Tissue Repair Feb 21, 2021 TB-500 / Thymosin beta 4 is made up of 43 amino acids, making it a oligopeptide, and has a molecular weight of 4.9 kDa. It is considered to be present in most tissues, with the exception of erythrocytes (

Thymosin Beta 4 (TB-500) and Tissue Repair

Feb 21, 2021

TB-500 / Thymosin beta 4 is made up of 43 amino acids, making it a oligopeptide, and has a molecular weight of 4.9 kDa. It is considered to be present in most tissues, with the exception of erythrocytes (red blood cells). The peptide was initially discovered as a protein isolate in the mammalian thymus gland. It belongs to a family of thymosins, acidic molecules that are light in weight and that function to produce cells. With that said, the motion and distinction of cells may potentially be manipulated by counteracting the power of singular monomers (or actin proteins) to polymerize into thin strands. In contrast, thymosins assemble the actin monomers, which may permit or deny the production of coming filaments. This may, to a degree, facilitate or inhibit the differentiation of a cell – such as a pluripotent stem cell into another (e.g. neurons or bone cells).

It follows that thymosin-like molecules (thymosin beta-4 being most prevalent in mammals) may potentially play a major function in tissue, cell regeneration or even postnatal development. TB-500’s potential influence over actin may extend to manipulating the migration of cells and the formation of new blood vessels. It is available as a lab-grade, synthetic peptide called TB-500 (Thymosin Beta 4).

Thymosin Beta 4 (TB-500) Peptide Research

The function of TB-500 to repair and regenerate tissue has been suggested through various experimental research studies. Thymosin Beta 4 has appeared to exhibit the ability to slow or prevent scar formation, microbial growth, cell death, and inflammation. TB-500, derived externally, may potentially act to hasten the repair of injured corneal, dermal, and cardiac tissues.

Studies in the peptide have suggested that it may play a role in repairing and regenerating various tissues, such as those of the peripheral nervous system, brain, heart, and spinal cord. TB-500 has been suggested to induce anti-inflammatory impacts as well as potentially presenting the power to weaken the discharge of prostaglandin EP4 and nitric oxide in cell models exposed to reactive oxygen species. Nevertheless, it may increase the stimulus response of pro-inflammatory chemokines and several interleukins in cells of the periodontium. Yet another research hypothesis for the action of TB-500 is that it may exhibit in the management of bone production, as these are osteoclastogenic molecules as well.In one study, NF-κB activation in murine macrophages appeared hindered by the peptide.

TB-500 is considered to be involved with the release of an anti-inflammatory peptide fragment called acSDKP – the metabolism of which is regulated by a number of interesting factors. The preparation of TB 500 together with integrated kidney tissue of rats reportedly produced a significant increase in the release of acSDKP7. Before the acSDKP split, this process is governed by an intricate governing mechanism which necessitates peptidases that split only the molecules of particular fragments, potentially involving TB-500 hydrolysis by meprin-alpha.

Researchers may find Thymosin beta-4 a possible research candidate within the context of fibrotic scarring of organs. Recently, results from a team of researchers have been published that present notable inflammation reductions in a rodent replica of pulmonary fibrosis. Also, acSDKP has presented a renal fibrosis reduction in rodents. The exposure to the fragment reportedly produced a decreased discharge of the major components of scar tissue (collagen and fibronectin), as well as a decrease in myofibroblast and macrophage migration to the damaged sites.

Hepatic stellate cell activation also appears to be associated with the up-regulation of TB-500. Generally, TB-500 considered to be connected with the intricate developmental and governing processes that take place in organisms in vivo. TB-500 appears to be a possible factor of tissue regeneration management, inflammation, and cell differentiation and may potentially prove interesting within the context of research on replicas of issues like rheumatoid arthritis, abnormal fibrosis, various states of postnatal development, and other forms of osteolytic inflammation.

Injury Repair

In one study using a murine model, TB 500 presented possible wound healing potential after being exposed to damaged tissue. Tissues were re-epithelialized by 42% over saline controls on the fourth day of the study; 61% on the seventh day after the injury occurred. An elevation in the discharge of collagen and formation of new blood vessels were reported in the exposed wound.

Eyes and Vision

In animal studies of various models, TB 500 was suggested to potentially restore eye-related impairments effectively – including injuries related to UV exposure, alkali, exposure to smoke, heptanol debridement, and ethanol exposure. In every situation, cell migration apparently induced by TB 500 appeared responsible for the repairs made to the injured/wounded region. The damaged eyes recovered quickly, and the migration increase with this peptide was reported.

Heart Muscles

In one study, TB-500 was exposed to soft tissue wounds in rodents. The wounds were in the center of the palate, and were three millimeters in diameter. Pictures of the wounded regions were taken and examined microscopically seven days after the procedure. The wound closure was reported to be significantly enhanced in rats that were exposed to Thymosin Beta 4, as compared to controls. In most cases, healing of oral cavity wounds is considered to happen more rapidly and may not scar as much as dermal tissue, which may result from the distinct phenotype of oral fibroblasts, and from particular salivary components. Nonetheless, damaged tissues resulting from implant and periodontal procedures are constantly confronted with a bacterial infection in the oral cavity, requiring detailed, cautious oral hygiene maintenance and increased management of plaque, regardless of the fairly quick wound healing. That is why, TB-500, which is suggested to improve the reconstruction of various tissue types, is anticipated to speed up the healing of mucosal wounds as well.

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

References:

Kim J, Wang S, Hyun J, et al. Hepatic Stellate Cells Express Thymosin Beta 4 in Chronically Damaged Liver. PloS one journal, 2015.

Philip D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of ageing and development, 2004.

Lee S-I, Yi J-K, Bae W-J, et al. Thymosin Beta-4 Suppresses Osteoclastic Differentiation and Inflammatory Responses in Human Periodontal Ligament Cells. PloS one journal, 2016.

Conte E, Genovese T, Gili E, et al. Protective effects of thymosin beta4 in a mouse model of lung fibrosis. Annals of the New York Academy of Sciences, 2012.

Sosne G, Kleinman HK; Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries. Invest. Ophthalmol. Vis. Sci, 2015.

Goldstein AL, Hannappel E, Sosne G & Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications, Expert Opinion on Biological Therapy, 2012.

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.

Latest Blog Articles

Thymogen Potential in Immune Cell Regulation

CJC-1295 & Hexarelin Blend Potential for Growth Hormone Signaling Stimulation

Oxytocin Actions On Neuronal Circuits in Different Mammalian Research Models

Kisspeptin 45-54 Peptide Interactions with Hypothalamic and Neuronal Cells

T-31 Peptide Interactions with Cellular Aging, Renewal, and Stress Pathways

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Weekly Dosing Reference · research convention, not a validated dose

Monday 30 750mcg Morning Thursday Weekly Total: 60 units (1,500mcg) • Vial Duration: ~17 days
STORAGE

Storage Requirements

Lyophilized (powder) Room temperature or refrigerated, protect from light Reconstituted Refrigerated 36-46F (2-8C), use within 30 days
02

Question drills

Open a question for its connected answer.

01What If I Use TB-500 Without Following My Physical Therapy Protocol?+

TB-500 enhances collagen deposition but does not restore proprioception, neuromuscular control, or quadriceps strength. All of which predict re-injury risk more reliably than graft tensile strength alone. A 2022 meta-analysis in Orthopedic Journal of Sports Medicine found that patients who achieved <90% limb symmetry index on hop testing at six months had 4.2× higher re-tear rates regardless of graft type. TB-500 cannot replace progressive loading, eccentric strengthening, or sport-specific agility training.

SOURCE / realpeptides.co ↗
02What If I Experience No Subjective Improvement After Two Weeks on TB-500?+

Continue the protocol through the full 4–6 weeks. Subjective pain reduction is only one marker. Collagen tensile strength and tissue remodeling occur over 6–8 weeks and aren't directly correlated with symptom relief. Many patients report delayed functional improvement around weeks 4–5 as newly synthesized collagen matures. If there's zero progress at week 6, reassess with imaging (MRI) to confirm the tear hasn't progressed and verify peptide storage/reconstitution wasn't compromised.

SOURCE / realpeptides.co ↗
03What If I Start TB-500 Two Weeks After My Meniscus Tear?+

Administer the peptide immediately. Delayed initiation still provides benefit, though outcomes may be 15–20% less robust compared to starting within 72 hours. The collagen deposition phase begins within days of injury, but remodelling continues for 8–12 weeks. TB-500 studied meniscus injury protocols show that even late administration (up to 14 days post-injury) improves tissue organisation and reduces chronic inflammation. Expect a longer protocol duration. 6–8 weeks instead of 4–6 weeks. To compensate for the delayed start.

SOURCE / realpeptides.co ↗
04What If I Inject TB-500 at Different Times Each Day?+

Variable injection timing has zero pharmacological impact on TB-500 efficacy as long as dosing intervals remain consistent (e.g., every 48 hours, or twice weekly). The peptide's extended half-life creates sustained plasma elevation that isn't disrupted by shifting the clock hour of administration. The real risk with irregular timing is missed doses. Researchers who anchor injection to a specific daily event (morning lab check-in, evening prep) show 20–30% better adherence than those using variable timing.

SOURCE / realpeptides.co ↗
05What If I Accidentally Froze Reconstituted TB-500?+

Discard it. Freezing reconstituted peptides forms ice crystals that mechanically shear peptide aggregates and disrupt the solution matrix. Upon thawing, the solution often appears cloudy or contains visible particulates—both signs of irreversible aggregation. Even if the solution looks clear after thawing, freeze-induced structural damage reduces biological activity unpredictably. The 28-day refrigerated stability window for reconstituted TB-500 assumes continuous refrigeration at 2–8°C without freezing. Freezing resets that window to zero.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Thymosin Beta-4 and Cardiac Research: Actin Sequestration Peptide, Cardiomyocyte Protection and Heart Repair Mechanisms UK 2026

This article is intended for researchers and laboratory professionals. All peptides discussed are for research use only (RUO) and are not approved for human administration, therapeutic use, or clinical application. PeptidesLab UK supplies research-grade Thymosin Beta-4 for in vitro and in vivo laboratory investigations only.

RESEARCH

Published Studies

Thymosin Beta-4 Ophthalmic Solution for Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Clinical Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC4445951/ Thymosin β4 Significantly Improves Signs and Symptoms of Severe Dry Eye Diseasehttps://pubmed.ncbi.nlm.nih.gov/25826322/ RGN-259 Thymosin β4 Improves Clinically Important Dry Eye Efficacy Measures in Comparison With Vehicle in a Phase 2 Clinical Trialhttps://www.nature.com/articles/s41598-018-28861-5 Comparative Study of Thymosin Beta-4 Eye Drops vs. Vehicle for Dry Eyehttps://clinicaltrials.gov/study/NCT01393132 Thymosin Beta-4 Accelerates Wound Healinghttps://pubmed.ncbi.nlm.nih.gov/10469335/ Thymosin Beta-4 Promotes Corneal Wound Healing and Decreases Inflammation In Vivo Following Alkali Injuryhttps://pubmed.ncbi.nlm.nih.gov/11950239/ Thymosin Beta-4 and a Synthetic Peptide Containing Its Actin-Binding Domain Promote Dermal Wound Repairhttps://pubmed.ncbi.nlm.nih.gov/12581423/ Recombinant Thymosin Beta-4 Can Promote Full-Thickness Cutaneous Wound Healing in BALB/c Micehttps://pubmed.ncbi.nlm.nih.gov/17923415/ Review Articles Thymosin β4: A Multifunctional Regenerative Peptidehttps://pubmed.ncbi.nlm.nih.gov/22074294/ Progress on the Function and Application of Thymosin β4https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/ Thymosin Beta-4 and the Eye: The Journey From Bench to Bedsidehttps://pubmed.ncbi.nlm.nih.gov/30063853/ Thymosin Beta-4: A Potential Novel Adjunct Treatment for Severe Refractory Atopic Dermatitishttps://pmc.ncbi.nlm.nih.gov/articles/PMC10403815/ Thymosin β4: A Potential Novel Dry Eye Therapyhttps://pubmed.ncbi.nlm.nih.gov/23050816/ The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice. This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, or outdated information. Thymosin Beta-4 is not FDA-approved for any medical indication in the United States. Any clinical use may be considered investigational or off-label depending on context. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment. R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law. # Thymosin Alpha-1 (Tα1)

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Related Comparisons & Guides

TB-4 Dosing Guide — Clinical and preclinical dosing protocols, reconstitution, and injection routes TB-4 Injury Recovery Guide — How TB-4 supports recovery from specific injury ty…